Walleye Capital
RARE icon

Walleye Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Walleye Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51M Buy
119,705
+83,221
+228% +$1.87M 0.01% 1288
2025
Q4 		$839K Sell
36,484
-31,449
-46% -$1.03M ﹤0.01% 2582
2025
Q3 		$2.04M Buy
67,933
+63,517
+1,438% +$1.9M 0.01% 1563
2025
Q2 		$161K Sell
4,416
-32,671
-88% -$1.18M ﹤0.01% 3524
2025
Q1 		$1.34M Buy
37,087
+25,890
+231% +$1.08M 0.01% 1743
2024
Q4 		$471K Sell
11,197
-37,920
-77% -$1.88M ﹤0.01% 3040
2024
Q3 		$2.73M Sell
49,117
-341,475
-87% -$17.4M 0.01% 1668
2024
Q2 		$16.1M Buy
390,592
+123,951
+46% +$5.29M 0.03% 471
2024
Q1 		$12.4M Buy
266,641
+114,914
+76% +$5.42M 0.02% 704
2023
Q4 		$7.26M Sell
151,727
-78,278
-34% -$3.03M 0.02% 861
2023
Q3 		$8.2M Buy
230,005
+210,141
+1,058% +$8.33M 0.02% 684
2023
Q2 		$916K Sell
19,864
-1,310
-6% -$60.8K ﹤0.01% 1924
2023
Q1 		$849K Buy
21,174
+15,906
+302% +$683K 0.01% 1294
2022
Q4 		$244K Buy
+5,268
New +$207K ﹤0.01% 1919

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Walleye Capital's RARE Position: Q1 2026 in Review

Walleye Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 228% in Q1 2026, buying an estimated $1.87M and bringing the position to 119,705 shares worth $2.51M. The position accounts for 0.01% of the portfolio, ranked #1288.

Walleye Capital first reported a position in RARE in Q4 2022 and has held it in 14 quarters since. The position peaked at $16.1M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Walleye Capital held 119,705 shares of Ultragenyx Pharmaceutical worth $2.51M as of Q1 2026.
  • Walleye Capital bought 83,221 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.87M.
  • Ultragenyx Pharmaceutical made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1288 holding.
  • Walleye Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
  • Walleye Capital's Ultragenyx Pharmaceutical position peaked at $16.1M in Q2 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.